European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis serogroup b fhbp (recombinant lipidated fhbp (factor h binding protein)) subfamily a; neisseria meningitidis serogroup b fhbp (recombinant lipidated fhbp (factor h binding protein)) subfamily b - meningitis, meningococcal - bacterial vaccines, meningococcal vaccines - trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by neisseria meningitidis serogroup b.the use of this vaccine should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

gsk vaccines s.r.l. - outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254), recombinant neisseria meningitidis group b fhbp fusion protein, recombinant neisseria meningitidis group b nada protein, recombinant neisseria meningitidis group b nhba fusion protein - meningitis, meningococcal - meningococcal vaccines - active immunisation against invasive disease caused by neisseria meningitidis serogroup-b strains.,

Canada - English - Health Canada

glaxosmithkline inc - recombinant neisseria meningitidis group b nhba fusion protein; recombinant neisseria meningitidis group b nada protein; recombinant neisseria meningitidis group b fhbp fusion protein; outer membrane vesicles (neisseria meningitidis group b nz98/254 strain) - suspension - 50mcg; 50mcg; 50mcg; 25mcg - recombinant neisseria meningitidis group b nhba fusion protein 50mcg; recombinant neisseria meningitidis group b nada protein 50mcg; recombinant neisseria meningitidis group b fhbp fusion protein 50mcg; outer membrane vesicles (neisseria meningitidis group b nz98/254 strain) 25mcg - vaccines

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - outer membrane vesicles (omv) from neisseria meningitidis group b containing the pora p1.4; neisseria meningitidis group b nhba fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b fhbp fusion protein - suspension for injection

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - neisseria meningitidis serogroup b recombinant lp2086 subfamily a protein; neisseria meningitidis serogroup b recombinant lp2086 subfamily b protein - injection, suspension - neisseria meningitidis serogroup b recombinant lp2086 subfamily a protein 0.06 mg/0.5ml; neisseria meningitidis serogroup b recombinant lp2086 subfamily b protein 0.06 mg/0.5ml

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - meningococcus b, multicomponent vaccine; meningococcus b, multicomponent vaccine - suspension for injection - meningococcus b, multicomponent vaccine 60 mcg; meningococcus b, multicomponent vaccine 60 mcg - meningococcus b, multicomponent vaccine - trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by neisseria meningitidis serogroup b.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

glaxo saudi arabia ltd, saudi arabia - recombinant neisseria meningitidis group b nhba fusion protein the nhba,recombinant neisseria meningitidis group b nhba fusion protein the nhba i,recombinant n meningitidis serogroup b nada protein,recombinant n meningitidis serogroup b nada protein i,recombinant n meningitidis serogroup b fhbp fusion protein,recombinant n meningitidis serogroup b fhbp fusion protein i,outer membrane vesicles from n meningitidis serogroup b strain nz98254 - suspension for injection in pre-filled syringe - 50,50,50,50,50,50,50 µg,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer europe ma eeig, belgium - meningococcal group a (neisseria meningitidis) polysaccharide vaccine,meningococcal group b (neisseria meningitidis) (strain nz98/254) - suspension for injection in pre-filled syringe - 60,60 µg,

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - neisseria meningitidis group b neisseria heparin binding antigen fusion protein, quantity: 50 microgram; neisseria meningitidis serogroup b outer membrane vesicles, quantity: 25 microgram; neisseria meningitidis group b factor h binding protein fusion protein, quantity: 50 microgram; neisseria meningitidis group b neisseria adhesin a protein, quantity: 50 microgram - injection, suspension - excipient ingredients: water for injections; aluminium hydroxide hydrate; histidine; sodium chloride; sucrose - bexsero is indicated for active immunisation against invasive disease caused by n. meningitidis group b strains. for information on protection against specific group b strains see section 5.1 pharmacodynamic properties. bexsero is indicated for vaccination of individuals from 2 months of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - neisseria meningitidis group b factor h binding protein fusion protein, quantity: 50 microgram; neisseria meningitidis group b neisseria adhesin a protein, quantity: 50 microgram; neisseria meningitidis serogroup b outer membrane vesicles, quantity: 25 microgram; neisseria meningitidis group b neisseria heparin binding antigen fusion protein, quantity: 50 microgram - injection, suspension - excipient ingredients: sucrose; histidine; water for injections; aluminium hydroxide hydrate; sodium chloride - bexsero is indicated for active immunisation against invasive disease caused by n. meningitidis group b strains. for information on protection against specific group b strains see section 5.1 pharmacodynamic properties. bexsero is indicated for vaccination of individuals from 2 months of age and older.